Targeting LMTK3 in ovarian cancer: A dual role in prognosis and therapy

Ovarian cancer (OC) remains one of the most lethal gynecological cancers, with limited treatment options, particularly for recurrent disease. To combat this, recent research has focused on identifying molecular drivers that could serve as novel therapeutic targets. In this context, Saed et al. present compelling evidence positioning lemur tail kinase 3 (LMTK3) as both a prognostic biomarker and a prospective novel therapeutic target in OC.1 Their study revealed that LMTK3 is expressed in >98% of early-stage OC tumor tissues (n = 204).